Bortun Ana-Maria Cristina, Ivan Viviana, Navolan Dan-Bogdan, Dehelean Liana, Borlea Andreea, Stoian Dana
PhD School Department, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Department of Internal Medicine II, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
J Clin Med. 2021 Jan 19;10(2):369. doi: 10.3390/jcm10020369.
The important prevalence of autoimmune thyroid disease (AITD) in the general population was the main motivation for conducting the present study. The present paper aims to estimate the possible comorbidities related to female sexual dysfunction (FSD) and depression related to AITD. The study group consisted of 320 patients: 250 cases known with untreated AITD, divided into subgroups (euthyroid subgroup, subclinical hypothyroidism subgroup and clinical hypothyroidism subgroup); respectively 70 healthy females in the control group. Patients underwent thyroid evaluation, ovarian evaluation and laboratory assays. At the time of the diagnosis of autoimmune thyroid disease, psychometric scales were filled in by the patients: the Female Sexual Function Index 6 (FSFI-6) and the Beck's Depression Inventory-II (BDI-II). It was observed that healthy patients had significantly higher FSFI scores than patients with AITD (28 vs. 27; = 0.006). In the AITD group, the risk of FSD increases with the severity of thyroid disease. The most affected areas were: sexual desire ( < 0.001), lubrication ( = 0.001) and orgasm ( = 0.008), followed by excitability and sexual satisfaction. The severity of hypothyroidism influences the degree of decrease in libido, central and peripheral excitability. Sexual satisfaction and orgasm were less influenced. The field related to pain seems uninfluenced by the presence of thyroid disease. The concomitant presence of depression and the value of thyroid-stimulating hormone (TSH) are risk factors in the development of FSD. Higher TSH value and BDI-II score increase the risk of female sexual dysfunction by 1.083 and 1.295 times, respectively. Our findings are significant and promising; they may help professionals dealing with sexual and reproductive health. Despite the importance of female sexual dysfunction and its prevalence, clinicians and patients often ignore it. In fact, only a small percentage of patients consult their doctors about sexual health, and their doctors do not often ask them questions related to this aspect.
自身免疫性甲状腺疾病（AITD）在普通人群中的高患病率是开展本研究的主要动机。本文旨在评估与AITD相关的女性性功能障碍（FSD）和抑郁症的可能合并症。研究组由320名患者组成：250例未经治疗的AITD患者，分为亚组（甲状腺功能正常亚组、亚临床甲状腺功能减退亚组和临床甲状腺功能减退亚组）；对照组分别为70名健康女性。患者接受了甲状腺评估、卵巢评估和实验室检测。在诊断自身免疫性甲状腺疾病时，患者填写了心理量表：女性性功能指数6（FSFI-6）和贝克抑郁量表-II（BDI-II）。观察到健康患者的FSFI评分显著高于AITD患者（28对27；P = 0.006）。在AITD组中，FSD的风险随着甲状腺疾病的严重程度而增加。受影响最严重的方面是：性欲（P < 0.001）、润滑（P = 0.001）和性高潮（P = 0.008），其次是兴奋性和性满意度。甲状腺功能减退的严重程度影响性欲、中枢和外周兴奋性的降低程度。性满意度和性高潮受影响较小。与疼痛相关的方面似乎不受甲状腺疾病存在的影响。抑郁症的并存和促甲状腺激素（TSH）的值是FSD发生的危险因素。较高的TSH值和BDI-II评分分别使女性性功能障碍的风险增加1.083倍和1.295倍。我们的研究结果具有重要意义且前景广阔；它们可能有助于处理性健康和生殖健康的专业人员。尽管女性性功能障碍很重要且患病率较高，但临床医生和患者往往忽视它。事实上，只有一小部分患者就性健康问题咨询医生，而且他们的医生也不经常询问他们与此相关的问题。
